PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in urology, today announced the launch of UroLift® Center of Excellence program to spotlight urologists dedicated to optimizing the treatment experience for patients treated with the company’s UroLift System.
The national program is designed to recognize exemplary care of men suffering from urinary tract symptoms and the achievement of a high level of training and experience with the UroLift System.
“The UroLift System is a proven technology with four years of published clinical data showing rapid and durable improvement of symptoms due to enlarged prostate,” said Dave Amerson, president and CEO of NeoTract. “We are excited to have many urologists around the country with extensive experience treating patients with the UroLift System, and this program is designed to highlight their commitment to providing the best care possible to their patients.”
The UroLift System permanent implants, delivered during a minimally-invasive procedure, act like window curtain tie-backs to hold the lobes of an enlarged prostate open. The procedure takes less than one hour and is typically performed using only local anesthetic in a physician’s office or ambulatory surgery center, with no cutting, heating, or removal of tissue. Patients recover from the procedure quickly, returning to their normal routines with minimal downtime.
The UroLift System is a proven treatment that can get men off BPH medications and allow them to avoid major surgery, while preserving sexual function. Long-term clinical data from the LIFT randomized study published in Urologic Clinics of North America showed that, after four years, patients treated with the UroLift device continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief.1 A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift device compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.2
More than 37 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life.
Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).
About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.UroLift.com.
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
# # #
1 Roehrborn Urology Clinics 2016
2 Sonksen et al J Urology 2016
MAC00358-01 Rev A